Neurocrine Bio. (NBIX) PT Raised to $145 at Piper Sandler Due to Ingrezza Long-Term Potential
Tweet Send to a Friend
Piper Sandler analyst David Amsellem raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $145.00 (from $141.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
